Healthcare
cbdMD, Inc.(YCBD)
Live Price
Offline$0.668
-0.30% today
1Y Change
-19.13%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $10.00M
- Revenue Growth
- -1.5%
- EPS Growth
- +39.1%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
cbdMD, Inc. (YCBD) is a Healthcare stock with a market cap of $10.00M and listed on AMEX. The stock last traded around $0.67 and down 19.1% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -1.5%, EPS growth of +39.1%, a dividend yield of 0.0%. What stands out right now is revenue -1.5%, EPS +39.1%, free cash flow -154.6% with operating margin -12.4% and ROIC -0.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines YCBD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.5% vs +7.6% peer median
Operating Margin
Below sector median
-12.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 20, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.5% and EPS is at +39.1%, with operating margin around -12.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +7.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 20, 2026 | โ | +4.1% | +10.4% | โ |
2026 Feb 17, 2026 | +33.3% | -6.8% | +20.4% | -3.0% |
2025 Dec 19, 2025 | -8.9% | -9.3% | -9.9% | -44.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
YCBD
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
YCBD Max Drawdown
-71.19%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for YCBD and SPY.
Company Overview
cbdMD, Inc.
New York Stock Exchange American
cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.
- Leadership
- T. Ronan Kennedy
- IPO Date
- Nov 17, 2017
- Employees
- 42
- Street Address
- 8845 Red Oak Boulevard
- Mailing
- Charlotte, NC, 28217
- Region
- Charlotte, NC, US
- Reporting Currency
- USD
- Investor Line
- 704 445 3060
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.5
- Price/Book
- 0.9
Growth
- Revenue
- -1.5%
- EPS
- +39.1%
- Free Cash Flow
- -154.6%
Profitability
- Gross Margin
- 55.0%
- Operating Margin
- -12.4%
- Net Margin
- -12.3%
- ROE
- -40.7%
- ROIC
- -0.4%
Balance Sheet
- Debt/Equity
- 65.83
- Current Ratio
- 2.94
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.